Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

327 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study.
Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Lovati C, Bertuzzo D, d'Onofrio F, Doretti A, Di Fiore P, Finocchi C, Schiano Di Cola F, Ranieri A, Colombo B, Bono F, Albanese M, Cevoli S, Barbanti P; GARLIT Study Group. Vernieri F, et al. Among authors: costa cm. Eur J Neurol. 2022 Apr;29(4):1198-1208. doi: 10.1111/ene.15197. Epub 2021 Dec 6. Eur J Neurol. 2022. PMID: 34826192
Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study).
Vernieri F, Altamura C, Aurilia C, Brunelli N, Egeo G, Fofi L, Costa CM, Fallacara A, Favoni V, Pierangeli G, Aguggia M, Bertuzzo D, Albanese M, Di Fiore P, Frediani F, Cevoli S, Barbanti P. Vernieri F, et al. Among authors: costa cm. Neurol Sci. 2020 Dec;41(Suppl 2):487-488. doi: 10.1007/s10072-020-04669-y. Neurol Sci. 2020. PMID: 32845481 No abstract available.
Drug withdrawal along with bridge therapy with methylprednisolone and/or diazepam for treatment of medication overuse headache: a preliminary report from the WASH-OUT study.
Vernieri F, Pasqualetti P, Paolucci M, Costa CM, Brunelli N, Autunno M, Fallacara A, Cecchi G, Cevoli S, Altamura C. Vernieri F, et al. Among authors: costa cm. Neurol Sci. 2020 Dec;41(Suppl 2):499-501. doi: 10.1007/s10072-020-04675-0. Neurol Sci. 2020. PMID: 32856233 No abstract available.
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study).
Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Pierangeli G, Lovati C, Aguggia M, d'Onofrio F, Doretti A, Di Fiore P, Finocchi C, Rao R, Bono F, Ranieri A, Albanese M, Cevoli S, Barbanti P; GARLIT Study Group. Vernieri F, et al. Among authors: costa cm. J Headache Pain. 2021 May 3;22(1):35. doi: 10.1186/s10194-021-01247-1. J Headache Pain. 2021. PMID: 33941080 Free PMC article.
Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
Barbanti P, Aurilia C, Cevoli S, Egeo G, Fofi L, Messina R, Salerno A, Torelli P, Albanese M, Carnevale A, Bono F, D'Amico D, Filippi M, Altamura C, Vernieri F; EARLY Study Group. Barbanti P, et al. Headache. 2021 Oct;61(9):1351-1363. doi: 10.1111/head.14194. Epub 2021 Jul 26. Headache. 2021. PMID: 34309862
Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study.
Vernieri F, Brunelli N, Messina R, Costa CM, Colombo B, Torelli P, Quintana S, Cevoli S, Favoni V, d'Onofrio F, Egeo G, Rao R, Filippi M, Barbanti P, Altamura C. Vernieri F, et al. Among authors: costa cm. J Headache Pain. 2021 Dec 18;22(1):154. doi: 10.1186/s10194-021-01363-y. J Headache Pain. 2021. PMID: 34922444 Free PMC article.
327 results